Reasons to buy the ‘Migraine’ market analysis report:
This report provides:
- Overview of migraine, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized migraine therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
- Key topics include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the migraine therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine treatment. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the global migraine therapeutics market. The report also covers an insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
How is our ‘Migraine in 68 Markets’ report unique from other reports in the market?
- Design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM migraine therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM migraine therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
We recommend this valuable source of information to anyone involved in:
- Pharma and Biotech Companies – CNS Drug Manufacturers and Suppliers
- Consulting and Professional Services (e.g., Investment Companies, Investment Banks, Equity Companies, etc.)
- Pharmaceutical Industry Suppliers/Pharma Manufacturers (Innovative, Biotech, Generics, Biosimilars, Rare/Orphan Disease)/Distributors
- Financial Institutions (Investors in Pharma/Biotech, Pricing Consultancies)/Parallel Trade Organisations
- Healthcare Organisations/Healthcare Technology Leaders and Start-ups
To Get a Snapshot of the Migraine in 68 Markets Report
Migraine Market in 68M Report Overview
The migraine market size across the 68M was $17.19 billion in 2023. The “Migraine in 68 Markets – Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033” market research report covers the 68 geographical markets and provides an Excel-based forecast model for the migraine market through 2033.
Migraine Market in 68M Outlook, 2023-2033 ($ Billion)
Buy the Full Report for More Insights on the Migraine Market in 68M Report Forecast
The report contains sales forecast extrapolations for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) and 61 geographical markets (61M). These extrapolations leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare and POLI Price Intelligence databases.
| Market Size (2023) | $17.19 Billion |
| Key Regions | · Africa
· APAC · Europe · LATAM · Middle East · North America |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Migraine Market in 68M Segmentation by Regions
The geographical regions encompassing the migraine market include Africa, APAC, Europe, LATAM, the Middle East, and North America. In 2023, North America accounted for the highest regional share of the migraine market across 68M.
Migraine Market in 68M Analysis by Regions, 2023 (%)
Buy the Full Report for More Regional Insights on Migraine Market in 68M
Download a Free Report Sample
Segments Covered in the Report
Migraine Market in 68M Regional Outlook (Value, $ Billion, 2023-2033)
- Africa
- APAC
- Europe
- LATAM
- Middle East
- North America
Key Stakeholders
Table of Contents
Tables
Table 1: Disease Migraine: Key Metrics in the 7MM
Table 2: Migraine Classification from the ICHD-3
Table 3: Diagnostic Criteria for Migraine with Aura
Table 4: Diagnostic Criteria for Migraine without Aura
Table 5: Risk Factors and Comorbidities for Migraine
Table 6: Treatment Guidelines for Disease Migraine
Table 7: Most Prescribed Drugs for Migraine by Class in the 7MM
Table 8: Migraine Market – Global Drivers and Barriers, 2020–2030
Table 9: Key Events Impacting Sales for Migraine in the US, 2020–2030
Table 10: Migraine Market – Drivers and Barriers in the US, 2020–2030
Table 11: Key Events Impacting Sales for Migraine in the 5EU, 2020–2030
Table 12: Migraine Market – Drivers and Barriers in the 5EU, 2020-2030
Table 13: Key Events Impacting Sales for Migraine in Japan, 2020–2030
Table 14: Migraine Market – Drivers and Barriers in Japan, 2020– 2030
Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
Graphs
Figure 1: Global Sales Forecast by Country for Migraine in 2020 and 2030
Figure 2: Analysis of the Company Portfolio Gap in Migraine During the Forecast Period
Figure 3: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC for Acute Migraine Treatment, Imitrex.
Figure 4: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against SOC for Preventive Migraine Treatment, generic propranolol.
Figure 5: Pathophysiology of a Migraine
Figure 6: 7MM, 12-Month Total Prevalence of Migraine, Men and Women, %, Ages ≥18 Years, 2020
Figure 7: 7MM, Sources Used and Not Used to Forecast the 12-Month Total Prevalent Cases of Migraine
Figure 8: 7MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Migraine by Frequency
Figure 9: 7MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Migraine by Type
Figure 10: 7MM, Sources Used to Forecast the Diagnosis Rate of Migraine
Figure 11: 7MM, 12-Month Total Prevalent Cases of Migraine, N, Both Sexes, Ages ≥18 Years, 2020
Figure 12: 7MM, 12-Month Total Prevalent Cases of Migraine by Age, N, Both Sexes, 2020
Figure 13: 7MM, 12-Month Total Prevalent Cases of Migraine by Sex, N, Ages ≥18 Years, 2020
Figure 14: 7MM, 12-Month Total Prevalent Cases of Migraine by Frequency, N, Both Sexes, Ages ≥18 Years, 2020
Figure 15: 7MM, 12-Month Total Prevalent Cases of Migraine by Type, N, Both Sexes, Ages ≥18 Years, 2020
Figure 16: 7MM, 12-Month Diagnosed Prevalent Cases of Migraine, N, Both Sexes, Ages ≥18 Years, 2020
Figure 17: Unmet Needs and Opportunities in Migraine
Figure 18: Overview of the Development Pipeline in Migraine
Figure 19: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for Migraine in the 7MM During the Forecast Period
Figure 20: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC for Acute Migraine Treatment, Imitrex.
Figure 21: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against SOC for Preventive Migraine Treatment, generic propranolol.
Figure 22: Analysis of the Company Portfolio Gap in Migraine During the Forecast Period
Figure 23: Global (7MM) Sales Forecast by Country for Migraine in 2020 and 2030
Figure 24: Global (7MM) Sales Forecast by Drug Class for Migraine in 2020 and 2030
Figure 25: Sales Forecast by Class for Migraine in the US in 2020 and 2030
Figure 26: Sales Forecast by Class for Migraine in the 5EU in 2020 and 2030
Figure 27: Sales Forecast by Class for Migraine in the Japan in 2020 and 2030










